Merck & Cie Wins $11.6M Over Acella's Supplements Marketing

Law360, New York (January 31, 2013, 9:46 PM EST) -- A New York federal judge on Thursday ordered Acella Pharmaceuticals LLC to pay $11.6 million in damages to drugmaker Merck & Cie Schaffhausen, finding that Acella falsely marketed its folate supplements as substitutes for Merck’s brand-name Metafolin, in violation of the Lanham Act.

Switzerland-based Merck & Cie, formerly known as Merck Eprova AG, brought the suit in 2009, alleging that Acella falsely sold its line of folate supplements as generic versions of Metafolin-containing products and informed national pharmaceutical databases that the generics were equivalent to the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Merck Eprova AG v. Brookstone Pharmaceuticals, LLC


Case Number

1:09-cv-09684

Court

New York Southern

Nature of Suit

Other Statutory Actions

Judge

Richard J. Sullivan

Date Filed

November 19, 2009

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.